New indication news: 73% of US clinicians, mostly dermatologists, would ignore the manufacturer's email first, and none would read more than three promotional emails a month
When a medicine they already prescribe gains a new FDA-approved indication, 73.2% of US clinicians on the Brox panel would ignore the manufacturer's email about it first, and 71.7% would rather hear first from a colleague, a conference, or a journal (n=198, October 2026).
- Who was asked
- US clinicians, 198 clones, US
- When
- October 2026 (fielded 20 October 2026)
- How
- Predicted responses from Brox clones, each built from a long-form interview with a real person.
- What changed from the obvious question
- The obvious question ranks channels by preference, which channel surveys already publish. This study asked three things about the same five channels (the first choice, the first to ignore and the one that would change prescribing), then what would get a clinician prescribing for the new indication within three months, and the number of promotional emails a month from one manufacturer they will still read, a threshold the published surveys do not give.
Section 01: What the panel said
- #
73.2%
73.2% of US clinicians would ignore the manufacturer's email first when a medicine they already prescribe gains a new indication, more than any other channel; nobody picked a colleague, a conference, or a journal as the one to ignore.
base 198
- #
73.7%
73.7% (146 of 198) would read at most one promotional email a month from any one drug manufacturer before ignoring or unsubscribing: 33.8% read none, 39.9% one, 26.3% two or three, and none would read more than three.
base 198
- #
82.3%
82.3% say a colleague, a conference, or a journal is the channel most likely to change what they prescribe, against 13.6% for a sales representative; a manufacturer's email, a medical science liaison, and an alert in the health record together change prescribing for 8 of 198.
base 198 · contrast
- #
62.6%
62.6% say confirmation that patients' insurance plans cover the new indication is what would most make them start prescribing for it within three months, against 24.7% for the full trial results and 5.1% for hearing that a respected colleague uses it; coverage leads in dermatology (68.3%, n=126) and outside it (52.8%, n=72).
base 198 · contrast
73.2% of US clinicians would ignore the manufacturer's email first when a medicine they already prescribe gains a new indication, more than any other channel; nobody picked a colleague, a conference, or a journal as the one to ignore.
02Why does the manufacturer's email lose before it is opened?
Because clinicians are not rejecting the manufacturer, they are rejecting the inbox. Of the 145 clones who would ignore the email first, 33 would still rather hear about a new indication from a sales representative, and 137 explain their answer with inbox volume: patient messages, results and hospital mail that bury anything promotional.
The ceiling is low and it is lower outside dermatology. 44.4% of the 72 clinicians outside dermatology read no promotional email from a manufacturer at all, against 27.8% of the 126 in dermatology, and in primary care it is 10 of 17.
03Is the sales representative still worth the visit?
For about a fifth of clinicians, yes, and for another fifth, no. 19.2% (n=198) want to hear about a new indication from a representative first, and 21.7% would ignore the representative first. The two groups barely overlap: 36 of the 43 who would ignore a representative want to hear first from a colleague, a conference, or a journal.
The representative is the only channel the manufacturer controls that has a following. Of the 38 clinicians who want the representative first, 25 say the representative is also what would change their prescribing. Email, a medical science liaison, and an alert in the record together change prescribing for 8 of 198.
04If journals and colleagues persuade, what sets the date?
The insurance plan. Of the 163 clinicians who say a colleague, a conference, or a journal is what would change their prescribing, 95 (58.3%) say confirmed coverage is what would get them prescribing for the new indication within three months. Only 10 of 198 name a respected colleague already using it.
The independent option is mostly about reading and meetings. Behind the 142 who want to hear first from a colleague, a conference, or a journal, the interview lines mention journals or other reading in 116 cases, conferences or meetings in 104 and colleagues in 73. Among the 124 who chose coverage, 93 explain it with prior authorization.
Outside dermatology the picture is less one-sided: coverage still leads at 52.8% (n=72), but 15 of those 72 would wait for the clinical guideline, which no dermatology clinician chose.
05What would a launch team do with this?
- Our reading: put the new-indication data where clinicians already read, in journals and at congresses, because that is the channel 82.3% (n=198) say changes their prescribing, and the manufacturer does not own it.
- Our reading: lead the launch message with coverage. A clinician who believes the data still waits for the plan, so "covered for this indication" may do more in the first quarter than another summary of the trial.
- Our reading: treat email as a ceiling, not a channel to scale. One a month is the most that 73.7% (n=198) will still read from one manufacturer.
06What else do people ask about this?
- What share of clinicians ignore pharma emails about a new indication? 73.2% of 198 US clinicians on the Brox panel would ignore the manufacturer's email first, more than any other channel (October 2026).
- How many promotional emails a month will a doctor read from one drug company? At most one for 73.7% (146 of 198): 33.8% read none, 39.9% one, 26.3% two or three, and none would read more than three.
- What share of clinicians need insurance coverage before prescribing a new indication? 62.6% (n=198) say confirmed coverage is what would get them prescribing within three months, against 24.7% for the full trial results.
Section 07: What they said, and the interview line it rests on
“I would definitely be most likely to ignore an email from the manufacturer. I get so flooded with emails on a daily basis that I'm completely emailed out, so those kinds of messages rarely catch my attention or make an impact. I'm much more inclined to pay attention to published trial data, discuss things with colleagues, hear about updates at meetings, or talk through new information when a rep or MSL stops by the office.”
Predicted from this line in the interview
“There's lots of emails, but I'm so emailed out that it's hard to really… doesn't really catch me, usually.”
“For me, it would definitely be hearing about it through a colleague, a conference talk, or a peer-reviewed journal article. If I already prescribe the drug, I'm already familiar with its general mechanism and safety, but to actually expand its use to a new indication, I need to see the clinical trial data and understand how peers are evaluating it. I go to a lot of conferences, stay on top of the literature, and discuss data with colleagues to see what their impression is. While reps and MSLs can provide notification or help navigate sample access, marketing and sales pitches don't drive my clinical decision-making. Seeing objective trial data published in journals or vetted at major meetings by trusted peers is what actually convinces me to change my prescribing habits.”
Predicted from this line in the interview
“I do think peer recommendations are are nice. You know, when I hear about a new drug, you know, I will discuss it with colleagues and see what their impression is and what their of the clinical trial data is, And then, yeah, I I have to see the the trial data before I decide if I wanna write something or not.”
“Definitely confirmation that my patients' insurance plans cover it. Since I already prescribe the medicine, I'm already familiar with how it works and its safety profile. In my solo practice, the biggest barrier to getting patients treated is insurance coverage. I've had so many instances where an effective medicine is approved, but insurance flat-out denies it or places it behind so many step-edits that the patient never gets it. I simply won't prescribe something if I know the patient can't access it or afford it, so knowing that their plans actually cover the new indication is what would truly allow me to start prescribing it within the next three months.”
Predicted from this line in the interview
“The insurance coverage overrides clinical preference. I've many times in the past prescribed medicine and it does not get covered, the patient doesn't receive it, so they are not getting any treatment of their condition.”
Section 08: How much should you trust this?
What we would defend
- The manufacturer's email is the channel most likely to be ignored first, at 73.2% (n=198), and it holds in dermatology (73.8%, n=126) and outside it (72.2%, n=72); 137 of the 145 clones who chose it explain the choice with inbox volume drawn from their interviews.
- 73.7% (146 of 198) would read at most one promotional email a month from one manufacturer and none would read more than three, as a stated ceiling.
- Confirmed insurance coverage is the leading trigger to prescribe for a new indication within three months, at 62.6% (n=198), in dermatology (68.3%, n=126) and outside it (52.8%, n=72); 93 of the 124 who chose it explain it with prior authorization.
What we would not
- The 82.3% and 71.7% for a colleague, a conference, or a journal as levels: one option bundled three independent sources against four single manufacturer channels, and it is the answer a good clinician is expected to give. Only the direction is defended: independent sources ahead of the best single manufacturer channel, the sales representative at 13.6% (n=198).
- That email does not work as a channel: other surveys find a rising share of clinicians prefer email for promotional contact, and this study asked only which ONE channel they would ignore first for news of a new indication.
- Anything beyond counts for primary care (17), surgical specialties (3) or nurse practitioners, physician assistants and pharmacists (6), including the 6 of 17 primary care clinicians who would prefer an alert in the health record.
- The 1 of 198 who would ignore an alert in the health record first, which sits oddly beside the alert-fatigue literature.
- Any split by age or gender: they are missing for 124 of the 198 clones.
The main limitation
These are 198 clones of US clinicians, 126 of them in dermatology, stating which channel they prefer, ignore and act on for an unnamed medicine; stated channel preference is not measured behavior, and the option that persuades most bundled colleagues, conferences and journals into one answer.
Section 09: How was this run?
| Segment | Clones |
|---|---|
| Dermatology | 126 |
| Another medical specialty | 46 |
| Primary care (family or internal medicine) | 17 |
| Nurse practitioner, physician assistant or pharmacist | 6 |
| A surgical specialty | 3 |
Question wording as fielded
- Do you currently prescribe at least one medicine to patients in your clinical practice? (added by Ask Brox as a screener)
- What is your main area of clinical practice?
- When a medicine you already prescribe is approved by the FDA for a new indication, which ONE of these is the way you would most like to first hear about it?
- When a medicine you already prescribe is approved by the FDA for a new indication, which ONE of these ways of hearing about it would you be most likely to ignore?
- When a medicine you already prescribe is approved by the FDA for a new indication, which ONE of these ways of hearing about it would be most likely to change what you actually prescribe?
- A medicine you already prescribe has just been approved by the FDA for a new indication that fits some of your patients. Which ONE of these would most make you start prescribing it for that indication within the next three months?
- What is the largest number of promotional emails a month from any one drug manufacturer that you would still read before you started ignoring or unsubscribing from them?
What was not asked, and why
No medicine, manufacturer, brand or condition was named. The study did not ask how clinicians actually heard about their last new indication (a recall question the clones cannot answer from data), did not split colleagues, conferences and journals into separate options, and did not test text messages, webinars, social media or a representative's own email. Ask Brox added one screener (do you currently prescribe at least one medicine), which all 198 passed.
What changed from the obvious question
The obvious question ranks channels by preference, which channel surveys already publish. This study asked three things about the same five channels (the first choice, the first to ignore and the one that would change prescribing), then what would get a clinician prescribing for the new indication within three months, and the number of promotional emails a month from one manufacturer they will still read, a threshold the published surveys do not give.
Fielded through Ask Brox on 20 October 2026.
More on How doctors decide what to prescribe · Pharma & HCP · HCP (US) panel
Ask this of your own customers: humans@brox.ai
Related insights
All in this topic-
Medical science liaisons: 60.1% of US physicians and other prescribers want real-world and subgroup evidence for patients like theirs, and 65.2% rate a liaison meeting useful against 17.7% for a sales rep
65.2% 65.2% rate a 20-minute meeting with a medical science liaison at least moderately useful to their practice, against 17.7% for a 20-minute meeting with a sales representative about the same kind of medicine (base 198)
Read -
Patient out-of-pocket cost and prescribing: US physicians keep a preferred brand at $25 a month, split at $75, and 62.9% switch to a generic at $150
37.1% 37.1% (26 of 70) would still prescribe the brand-name medicine they prefer when it costs the patient $150 a month against $5 for an older generic, down from 95.7% (67 of 70) at $25 and 55.7% (39 of 70) at $75; none of the 70 moves back to the brand as the price rises. (base 70)
Read -
New medicine launches: 72.9% of US physicians and other prescribers would try one in its first months when it is covered, 22.9% when patients pay $250 a month
22.9% 22.9% (16 of 70) are likely, a 6 or 7 of 7, to prescribe a new medicine with a clear phase 3 benefit in the next three months when most plans do not cover it and a patient pays about $250 a month, against 72.9% (51 of 70) when it is covered with no prior authorization and a $30 copay, and 54.3% (38 of 70) when prior authorization takes one to two weeks. (base 70)
Read -
Pharma rep visits: 66.7% of US clinicians, mostly dermatologists, would turn away a rep who asks to come every two weeks, against 39.4% for a monthly visit
66.7% Asked by a rep for a medicine they already prescribe for a 10-minute in-person visit, 66.2% of US clinicians would agree to one every three months, 58.1% to one a month and 31.8% to one every two weeks; the share who would decline rises from 30.8% to 39.4% to 66.7%. (base 198)
Read